Anavex Life Sciences Corp. (AVXL) Stock Price Hits Yearly Low Today

April 17, 2018 - By Marie Mckinney

Anavex Life Sciences Corp. (NASDAQ:AVXL) Logo

The stock of Anavex Life Sciences Corp. (NASDAQ:AVXL) hit a new 52-week low and has $2.05 target or 3.00 % below today’s $2.12 share price. The 8 months bearish chart indicates high risk for the $94.38M company. The 1-year low was reported on Apr, 17 by If the $2.05 price target is reached, the company will be worth $2.83 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.05% or $0.1126 during the last trading session, reaching $2.1174. About 979,155 shares traded or 228.85% up from the average. Anavex Life Sciences Corp. (NASDAQ:AVXL) has declined 55.59% since April 17, 2017 and is downtrending. It has underperformed by 67.14% the S&P500.

Analysts await Anavex Life Sciences Corp. (NASDAQ:AVXL) to report earnings on May, 9. They expect $-0.10 EPS, down 11.11 % or $0.01 from last year’s $-0.09 per share. After $-0.09 actual EPS reported by Anavex Life Sciences Corp. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The company has market cap of $94.38 million. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. It currently has negative earnings. The Company’s preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.